The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease
Atherosclerosis Sep 01, 2021
Kim H, Park JT, Lee J, et al. - Patients with chronic kidney disease (CKD) were noted to be at a higher risk of major adverse cardiovascular events (MACE) and faster coronary artery calcification (CAC) progression in presence of a large positive difference between creatinine-based estimated glomerular filtration rate (eGFRcreat) and cystatin C-based estimated glomerular filtration rate (eGFRcys). Patients with a higher estimated glomerular filtration rate difference (eGFRdiff; calculated by subtracting the eGFRcys from the eGFRcreat should be carefully monitored for cardiovascular disease.
Prospective cohort study in 2,076 patients with CKD stages.
One hundred forty-seven patients had occurrence of MACE during a median follow-up of 4.1 years, (incidence rate, 15.0 per 1,000 patient-years).
When patients were categorized into baseline eGFRdiff tertiles, a significantly higher risk of MACE was observed in correlation with the highest tertile relative to the lowest tertile.
More baseline coronary artery calcification (CAC) was recorded in patients in the highest tertile vs those in the lowest tertile.
Significant association of baseline eGFRdiff with accelerated CAC progression (≥ 50/year) was evident.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries